Pfizer and Flynn Pharma were fined a record amount for abusing their dominant position in the UK by charging unfair prices for unbranded versions of the Epanutin anti-epilepsy drug.

Drug firms Pfizer and Flynn Pharma have been fined nearly £90m (€106m) for "excessive and unfair" pricing to the NHS after hiking the cost of an anti-epilepsy drug by up to 2,600% overnight.

Britain’s competition watchdog has accused Pfizer and Flynn Pharma of breaching UK and European law by ramping up the cost of an epilepsy drug, given to more than 50,000 British patients, by as much as 2,600%.